AU2014361814A1 - Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders - Google Patents
Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders Download PDFInfo
- Publication number
- AU2014361814A1 AU2014361814A1 AU2014361814A AU2014361814A AU2014361814A1 AU 2014361814 A1 AU2014361814 A1 AU 2014361814A1 AU 2014361814 A AU2014361814 A AU 2014361814A AU 2014361814 A AU2014361814 A AU 2014361814A AU 2014361814 A1 AU2014361814 A1 AU 2014361814A1
- Authority
- AU
- Australia
- Prior art keywords
- agx51
- cancer
- compound
- cells
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361916116P | 2013-12-13 | 2013-12-13 | |
| US61/916,116 | 2013-12-13 | ||
| US201461965776P | 2014-02-06 | 2014-02-06 | |
| US61/965,776 | 2014-02-06 | ||
| PCT/US2014/070221 WO2015089495A2 (en) | 2013-12-13 | 2014-12-14 | Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2014361814A1 true AU2014361814A1 (en) | 2016-07-28 |
Family
ID=53371974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014361814A Abandoned AU2014361814A1 (en) | 2013-12-13 | 2014-12-14 | Compositions and methods for treating, preventing and diagnosing cancer and other proliferative disorders |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3079680A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2017506257A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107847470A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014361814A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016007748A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015089495A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) * | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| JP6803339B2 (ja) | 2015-04-21 | 2020-12-23 | エンリヴェックス セラピューティクス リミテッド | 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用 |
| JP6884155B2 (ja) | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | 癌治療のための併用免疫療法及びサイトカイン制御療法 |
| LU100900B1 (de) * | 2018-08-10 | 2020-02-17 | Thomas Melchior Homann | Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen |
| EP3760614B8 (en) * | 2019-07-02 | 2022-04-27 | Universität Heidelberg | Chemical inhibitors of id proteins for the treatment of cancer and other diseases |
| JP7880815B2 (ja) * | 2019-10-01 | 2026-06-26 | メモリアル スローン-ケタリング キャンサー センター | Idタンパク質の小分子阻害剤 |
| CN113627763B (zh) * | 2021-07-30 | 2023-12-01 | 厦门大学 | 一种风险量化评估模型建立方法 |
| CN114480490A (zh) * | 2021-12-31 | 2022-05-13 | 四川省医学科学院·四川省人民医院 | 一种构建视网膜新生血管性疾病动物模型的方法 |
| CN115487358B (zh) * | 2022-08-05 | 2023-05-30 | 核工业四一六医院 | 一种用于软骨组织修复的凝胶复合支架及制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8138356B2 (en) * | 2007-10-16 | 2012-03-20 | Angiogeney, Inc. | Chemical inhibitors of inhibitors of differentiation |
| US20130171158A1 (en) * | 2010-06-30 | 2013-07-04 | Garvan Institute Of Medical Research | Treatment of abnormalities of glucose metabolism with an antagonist of inhibitor of differentiation 1 |
| WO2013025939A2 (en) * | 2011-08-16 | 2013-02-21 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
-
2014
- 2014-12-14 MX MX2016007748A patent/MX2016007748A/es unknown
- 2014-12-14 EP EP14870415.8A patent/EP3079680A4/en not_active Withdrawn
- 2014-12-14 AU AU2014361814A patent/AU2014361814A1/en not_active Abandoned
- 2014-12-14 CN CN201480075495.2A patent/CN107847470A/zh active Pending
- 2014-12-14 WO PCT/US2014/070221 patent/WO2015089495A2/en not_active Ceased
- 2014-12-14 JP JP2016558543A patent/JP2017506257A/ja active Pending
-
2019
- 2019-09-06 JP JP2019162598A patent/JP2019203028A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN107847470A (zh) | 2018-03-27 |
| WO2015089495A2 (en) | 2015-06-18 |
| EP3079680A2 (en) | 2016-10-19 |
| MX2016007748A (es) | 2017-07-28 |
| JP2017506257A (ja) | 2017-03-02 |
| WO2015089495A3 (en) | 2015-11-12 |
| EP3079680A4 (en) | 2017-11-22 |
| JP2019203028A (ja) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019203028A (ja) | 癌及びその他の増殖性疾患の治療、予防及び診断のための組成物並びに方法 | |
| Zhang et al. | Polo-like kinase 4’s critical role in cancer development and strategies for Plk4-targeted therapy | |
| EP4186501B1 (en) | Drug therapy to inhibit chemotherapy-induced adverse effects and related pharmaceutical compositions, diagnostics, screening techniques and kits | |
| JP2023145689A (ja) | Her2陽性がんの処置 | |
| WO2009051801A2 (en) | Chemical inhibitors of inhibitors of differentiation | |
| ES2992827T3 (en) | Combination therapies targeting mitochondrial biogenesis for cancer therapy | |
| JP7611701B2 (ja) | Abcb5のリガンドおよび基質 | |
| JP2022180472A (ja) | 癌のための併用療法 | |
| EP3003356B1 (en) | Il-1 antagonists for use in treating alzheimer's disease | |
| WO2016040877A1 (en) | Human dosing of phosphatase inhibitor | |
| US20140348819A1 (en) | Methods of Treating Cancer | |
| WO2014082085A1 (en) | Use of itk inhibitors for the treatment of cancer | |
| ES2905360T3 (es) | Composiciones y métodos para detectar, tratar y prevenir enfermedades y trastornos | |
| CN105377295A (zh) | 基于caix分级的癌症治疗 | |
| US20190111111A1 (en) | Treatment of Cerebral Cavernous Malformations | |
| Yu et al. | Elevation of the chemokine pair CXCL10/CXCR3 initiates sequential glial activation and crosstalk during the development of bimodal inflammatory pain after spinal cord ischemia reperfusion | |
| US20220280590A1 (en) | Use of inhibitors of yap and sox2 for the treatment of cancer | |
| Alexandraki et al. | Medical therapy for craniopharyngiomas | |
| Tada et al. | The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma | |
| WO2004043340A2 (en) | Alpha 5 beta 1 and its ability to regulate the cell survival pathway | |
| van Genugten et al. | Imaging the rewired metabolism in lung cancer in relation to immune therapy | |
| US20200023038A1 (en) | Method of treating neoplasias | |
| KR20260008112A (ko) | 파르네실트랜스퍼라제 억제제 및 pi3k 억제제를 사용한 편평 세포 암종의 치료 방법 | |
| CN120265328A (zh) | 用于非小细胞肺癌的检测和治疗的方法 | |
| US9566334B2 (en) | Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |